PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 3389721

[Cholestatic hepatitis caused by ketoconazole].

R J Bensaude·Y Furet·E Autret·H Brottes·J L Billard·M Breteau
View original source ↗Export metadata ↓

Abstract

The authors report a new Ketoconazole-induced hepatitis in which clinical, chemical and histological features show evidence of a cholestatic injury in a 62 yrs-old female recovering once therapy is stopped. In this case-report, delay of onset of the illness is very short for a 200 mg-a-day prescription and no feature leads towards an immune response. This, may be, means that Ketoconazole-induced hepatitis should be led by an idiosyncrasic mechanism. Even if fatal hepatitis are rare, prescriptors have to beware of this therapy.

Explore related subjects

Chemical and Drug Induced Liver InjuryCholestasis, IntrahepaticFemaleHumansKetoconazoleMiddle AgedCase ReportsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R J Bensaude, Y Furet, E Autret, H Brottes, J L Billard, M Breteau. [Cholestatic hepatitis caused by ketoconazole].. https://pubmed.ncbi.nlm.nih.gov/3389721/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent.

BACKGROUND: Methotrexate-induced liver damage in psoriasis has led to dermatologic guidelines that stipulate monitoring of liver injury by means of serial liver biopsies. Recent literature data suggest that methotrexate may be considerably less hepatotoxic than previously assumed. AIM: To evaluate prevalence and development of liver injury in methotrexate treated psoriasis. METHODS: Retrospective chart review (1976-2005). RESULTS: Hundred and twenty-five patients (F58/M67; mean age 45.0, SD 12.7 years) received a median cumulative methotrexate dose of 2,113 mg (range 180-20 235) over a median period of 228 weeks (range 16-1763). Two hundred and seventy eight liver biopsies were analysed and 71% were classified as Roenigk grade I, 14% as Roenigk II, 14% grade IIIa, 2% grade IIIB and 2% grade IV. Liver injury was not associated with cumulative dose, weekly prescribed dose, age or duration of treatment. Obesity and diabetes were significant risk factors for liver injury. A total of 68 patients had multiple biopsies, 3% improved, 72% did not change and in 25% liver histology deteriorated. The majority of cases (84%) that progressed to Roenigk 2 had a cumulative dose of 1,500-6,000 mg. CONCLUSIONS: Methotrexate-related liver injury is less frequent than previously thought and mostly occurred at cumulative dose of <6,000 mg. Diabetes and being overweight are significantly correlated with liver injury.

Chemical and Drug Induced Liver Injury↗